The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 29, 2019
Filed:
Oct. 03, 2013
Applicant:
Sarcode Bioscience Inc., Brisbane, CA (US);
Inventors:
Thomas Gadek, Oakland, CA (US);
John Burnier, Pacifica, CA (US);
Assignee:
SARCODE BIOSCIENCE INC., Brisbane, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 405/06 (2006.01); A61K 31/4725 (2006.01); C07D 217/00 (2006.01); C07D 217/02 (2006.01); A61K 31/198 (2006.01); A61K 31/404 (2006.01); A61K 31/4162 (2006.01); A61K 31/4184 (2006.01); A61K 31/4192 (2006.01); A61K 31/44 (2006.01); A61K 31/4709 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/54 (2006.01); A61K 31/541 (2006.01); A61K 31/381 (2006.01); A61K 45/06 (2006.01); C07D 333/38 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); A61K 33/00 (2006.01); A61K 33/06 (2006.01); C07D 217/20 (2006.01); C07D 217/06 (2006.01); A61K 31/405 (2006.01); A61K 31/495 (2006.01); A61K 38/07 (2006.01); A61K 38/08 (2006.01); A61K 38/12 (2006.01); A61K 38/17 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); A61K 31/197 (2006.01); A61K 31/341 (2006.01); A61K 31/352 (2006.01); A61K 31/472 (2006.01); C07D 401/06 (2006.01); A61K 31/275 (2006.01); A61K 31/40 (2006.01); A61K 31/517 (2006.01); C07C 279/28 (2006.01); C07C 317/50 (2006.01); C07D 207/06 (2006.01); C07D 217/26 (2006.01); C07D 307/52 (2006.01); C07D 413/14 (2006.01); A61K 9/00 (2006.01); G01N 33/566 (2006.01); A61B 3/10 (2006.01); A61B 3/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4725 (2013.01); A61B 3/101 (2013.01); A61B 3/145 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0048 (2013.01); A61K 9/0051 (2013.01); A61K 9/0053 (2013.01); A61K 31/197 (2013.01); A61K 31/198 (2013.01); A61K 31/275 (2013.01); A61K 31/341 (2013.01); A61K 31/352 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/404 (2013.01); A61K 31/405 (2013.01); A61K 31/4162 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/44 (2013.01); A61K 31/472 (2013.01); A61K 31/4709 (2013.01); A61K 31/4745 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/54 (2013.01); A61K 31/541 (2013.01); A61K 33/00 (2013.01); A61K 33/06 (2013.01); A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 38/12 (2013.01); A61K 38/1703 (2013.01); A61K 45/06 (2013.01); C07C 279/28 (2013.01); C07C 317/50 (2013.01); C07D 207/06 (2013.01); C07D 217/00 (2013.01); C07D 217/02 (2013.01); C07D 217/06 (2013.01); C07D 217/20 (2013.01); C07D 217/26 (2013.01); C07D 307/52 (2013.01); C07D 333/38 (2013.01); C07D 401/06 (2013.01); C07D 405/06 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); G01N 33/5011 (2013.01); G01N 33/5032 (2013.01); G01N 33/5047 (2013.01); G01N 33/566 (2013.01); G01N 33/6872 (2013.01); G01N 2333/705 (2013.01); G01N 2333/70525 (2013.01); G01N 2333/70546 (2013.01); G01N 2500/02 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01); G01N 2500/20 (2013.01); G01N 2800/16 (2013.01); Y10S 514/912 (2013.01); Y10S 514/914 (2013.01);
Abstract
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.